CONNEX Study
Why participating in clinical trials would be a positive experience:
Access to innovative treatments
Close monitoring and expert care
Contribute to medical knowledge
Support for your condition
Financial compensation for your time and travel
The CONNEX program includes three separate studies
Depending on which study they join, participants in CONNEX will be in a study for approximately 8 months (35 weeks). Participants will also be asked to attend up to 15 study clinic visits.
CONNEX will compare the effects of an investigational drug with an inactive drug (a placebo).
Placebo is a tablet that looks like an investigational drug but contains no active ingredients. Participants in CONNEX will be randomly assigned to receive either the investigational drug or placebo.
Requirements you must meet:
18-50 years old (at the time of joining)
Have been diagnosed with schizophrenia
Be taking the same medication for at least 3 months
Have not been treated in a hospital for schizophrenia within the last 3 months
Be experiencing difficulty remembering things, staying focused on tasks or conversations, or figuring out how to do something
Be able to attend study visits with a friend or family member who you see and speak to, for a minimum of 1 hour/week, twice a week (“study partner”)
Download the CONNEX material and take it with you:
ADEPT-1 Study
Evaluating the safety and efficacy of KarXT, an investigational drug, for the treatment of psychosis associated with Alzheimer’s disease dementia.
ERUDITE Study
Evaluating the effectiveness of the investigational medication, Luvadaxistat, in individuals with schizophrenia, to improve their cognitive function.
JOURNEY2 Study
Asking if an investigational drug can improve cognition in people with schizophrenia